Cargando…
Lipid droplet‐mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib
Ponatinib is a small molecule multi‐tyrosine kinase inhibitor clinically approved for anticancer therapy. Molecular mechanisms by which cancer cells develop resistance against ponatinib are currently poorly understood. Likewise, intracellular drug dynamics, as well as potential microenvironmental fa...
Autores principales: | Englinger, Bernhard, Laemmerer, Anna, Moser, Patrick, Kallus, Sebastian, Röhrl, Clemens, Pirker, Christine, Baier, Dina, Mohr, Thomas, Niederstaetter, Laura, Meier‐Menches, Samuel M., Gerner, Christopher, Gabler, Lisa, Gojo, Johannes, Timelthaler, Gerald, Senkiv, Julia, Jäger, Walter, Kowol, Christian R., Heffeter, Petra, Berger, Walter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497038/ https://www.ncbi.nlm.nih.gov/pubmed/32064608 http://dx.doi.org/10.1002/ijc.32924 |
Ejemplares similares
-
Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer
por: Englinger, Bernhard, et al.
Publicado: (2017) -
Lysosomal Sequestration Impairs the Activity of the Preclinical FGFR Inhibitor PD173074
por: Englinger, Bernhard, et al.
Publicado: (2018) -
Development of a cobalt(iii)-based ponatinib prodrug system
por: Mathuber, Marlene, et al.
Publicado: (2021) -
A Phase II Study of the Multikinase Inhibitor Ponatinib in Patients With Advanced, RET-Rearranged NSCLC
por: Gainor, Justin F., et al.
Publicado: (2020) -
Trabectedin Is Active against Two Novel, Patient-Derived Solitary Fibrous Pleural Tumor Cell Lines and Synergizes with Ponatinib
por: Ghanim, Bahil, et al.
Publicado: (2022)